INOVIO PHARMACEUTICALS INC's ticker is INO and the CUSIP is 45773H201. A total of 187 filers reported holding INOVIO PHARMACEUTICALS INC in Q2 2022. The put-call ratio across all filers is 1.11 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $31,000 | +342.9% | 77,760 | +433.2% | 0.00% | – |
| Q2 2023 | $7,000 | -69.6% | 14,583 | -48.6% | 0.00% | – |
| Q1 2023 | $23,000 | -96.0% | 28,384 | -92.2% | 0.00% | – |
| Q4 2022 | $570,000 | +475.8% | 365,230 | +533.7% | 0.00% | – |
| Q3 2022 | $99,000 | +80.0% | 57,636 | +78.8% | 0.00% | – |
| Q2 2022 | $55,000 | -66.3% | 32,227 | -28.9% | 0.00% | – |
| Q1 2022 | $163,000 | -78.3% | 45,342 | -69.8% | 0.00% | – |
| Q4 2021 | $750,000 | +48.8% | 150,216 | +113.2% | 0.00% | – |
| Q3 2021 | $504,000 | +5.0% | 70,447 | +36.1% | 0.00% | – |
| Q2 2021 | $480,000 | +8.6% | 51,749 | +8.4% | 0.00% | – |
| Q1 2021 | $442,000 | +101.8% | 47,746 | +92.8% | 0.00% | – |
| Q4 2020 | $219,000 | +9.5% | 24,765 | +43.6% | 0.00% | – |
| Q3 2020 | $200,000 | -65.2% | 17,249 | -19.1% | 0.00% | – |
| Q2 2020 | $575,000 | +160.2% | 21,317 | -28.1% | 0.00% | – |
| Q1 2020 | $221,000 | +7266.7% | 29,668 | +3241.0% | 0.00% | – |
| Q4 2019 | $3,000 | +200.0% | 888 | +77.6% | 0.00% | – |
| Q3 2019 | $1,000 | -98.8% | 500 | -98.2% | 0.00% | – |
| Q2 2019 | $82,000 | -80.8% | 28,000 | -75.5% | 0.00% | – |
| Q1 2019 | $426,000 | -4.1% | 114,100 | +2.7% | 0.00% | – |
| Q4 2018 | $444,000 | -31.3% | 111,100 | -4.4% | 0.00% | – |
| Q3 2018 | $646,000 | +48.2% | 116,205 | +4.6% | 0.00% | – |
| Q2 2018 | $436,000 | +1457.1% | 111,110 | +1751.8% | 0.00% | – |
| Q1 2018 | $28,000 | +55.6% | 6,000 | +37.4% | 0.00% | – |
| Q4 2017 | $18,000 | -78.3% | 4,367 | -66.6% | 0.00% | – |
| Q3 2017 | $83,000 | +159.4% | 13,088 | +224.4% | 0.00% | – |
| Q2 2017 | $32,000 | -8.6% | 4,034 | -23.2% | 0.00% | – |
| Q1 2017 | $35,000 | -5.4% | 5,254 | -0.8% | 0.00% | – |
| Q4 2016 | $37,000 | +54.2% | 5,299 | +109.9% | 0.00% | – |
| Q3 2016 | $24,000 | -11.1% | 2,525 | -13.7% | 0.00% | – |
| Q2 2016 | $27,000 | -42.6% | 2,925 | -46.1% | 0.00% | – |
| Q1 2016 | $47,000 | +1466.7% | 5,425 | +1188.6% | 0.00% | – |
| Q4 2015 | $3,000 | -85.7% | 421 | -88.1% | 0.00% | – |
| Q3 2015 | $21,000 | +950.0% | 3,543 | +1474.7% | 0.00% | – |
| Q2 2015 | $2,000 | -90.9% | 225 | -90.4% | 0.00% | – |
| Q4 2014 | $22,000 | +144.4% | 2,344 | +145.2% | 0.00% | – |
| Q3 2014 | $9,000 | -30.8% | 956 | -20.7% | 0.00% | – |
| Q2 2014 | $13,000 | – | 1,206 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| CAXTON ASSOCIATES LP | 784,679 | $643,437 | 0.10% |
| Green Alpha Advisors, LLC | 146,300 | $119,966 | 0.08% |
| Virtus ETF Advisers LLC | 54,106 | $44,367 | 0.02% |
| Cedar Brook Financial Partners, LLC | 104,881 | $86,002 | 0.02% |
| PROFUND ADVISORS LLC | 418,749 | $343,374 | 0.02% |
| Arlington Capital Management, Inc. | 27,735 | $22,743 | 0.02% |
| Hennion & Walsh Asset Management, Inc. | 382,158 | $313 | 0.02% |
| Rafferty Asset Management, LLC | 2,647,927 | $2,171,300 | 0.02% |
| Brainard Capital Management LLC | 16,666 | $13,666 | 0.01% |
| Beck Bode, LLC | 41,218 | $33,799 | 0.01% |